Last reviewed · How we verify
Daypro (Oxaprozin)
Daypro (Oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) developed by GD Searle and currently owned by Solubiomix. It targets complement C5 and is used to treat juvenile rheumatoid arthritis, osteoarthritis, and rheumatoid arthritis. Daypro has a high bioavailability of 98% and a half-life of 22 hours, making it a viable treatment option. The drug is off-patent, with 13 generic manufacturers available. Key safety considerations include its potential to cause gastrointestinal and renal side effects.
At a glance
| Generic name | Oxaprozin |
|---|---|
| Sponsor | Solubiomix |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Target | Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1992 |
Approved indications
- Juvenile rheumatoid arthritis
- Osteoarthritis
- Rheumatoid arthritis
Boxed warnings
- WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions (5.1)]. Oxaprozin is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings and Precautions (5.2)].
Common side effects
- Gastrointestinal ulcers (gastric/duodenal)
- Gross bleeding/perforation
- Edema
- Abdominal pain/distress
- Anorexia
- Constipation
- Diarrhea
- Dyspepsia
- Flatulence
- Heartburn
- Liver enzyme elevations
- Nausea
Drug interactions
- phenprocoumon
- warfarin
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daypro CI brief — competitive landscape report
- Daypro updates RSS · CI watch RSS
- Solubiomix portfolio CI